Autologous cell therapy in patients with ALS can stimulate neuroplasticity, modifying the neurodegenerative process and stops the clinical progression of disease.
There is no more extensive information
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
14
Mobilization and collection of stem cells for intravenous and intrathecal administration
Servicio Hematología Hospital Universitario
Monterrey, Nuevo León, Mexico
Evaluation of autologous intrathecal administration of hematopoietic stem cells in patients with ALS.
Time frame: up to 12 months
To evaluate the safety of intrathecal administration of hematopoietic stem cells in patients with ALS.
Time frame: During the procedure and at 1st, 2nd, 3rd, 6th and 12 th month after the procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.